DoW Neurofibromatosis Investigator-Initiated Research Award
This grant funds impactful, non-clinical trial research on neurofibromatosis, with options for open data sharing and collaboration, requiring relevant preliminary or published data.
Funder: Defense Health Agency Contracting Activity - DHACA
Due Dates: September 8, 2026: Letter of Intent (pre-application) | September 22, 2026: Full application | September 28, 2026: End of application verification period
Funding Amounts: Up to $840,000 (Level 1) or $920,000 (Level 2) total costs per award over 3 years; ~7 awards anticipated; total program funding $6.04M.
Summary: Supports high-impact, rigorous research (excluding clinical trials) to advance understanding or care in neurofibromatosis, with options for open science data sharing and/or qualified collaboration.
Key Information: Applications must include relevant preliminary or published data; clinical trials are not permitted.
Description
This opportunity supports investigator-initiated, high-impact research that addresses critical needs in neurofibromatosis (NF) or advances patient care. Projects may focus on any research phase except clinical trials. The program encourages innovative approaches, multidisciplinary collaboration, and open science practices. Research must be substantiated with relevant preliminary or published data. Two funding levels are available: a standard level and an enhanced level for projects that include either participation in the Open Science Initiative or a qualified collaborator.
